Targeted systemic DMARDs in psoriatic arthritis
Cyclosporine in psoriatic arthropathy
A. Soriano1, N. Pipitone2, C. Salvarani3
- Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.
- Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.
- Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia; and University of Modena and Reggio Emilia, Italy. salvarani.carlo@asmn.re.it
CER8995
2015 Vol.33, N°5 ,Suppl.93
PI 0101, PF 0103
Targeted systemic DMARDs in psoriatic arthritis
Free to view
(click on article PDF icon to read the article)
PMID: 26470797 [PubMed]
Received: 22/09/2015
Accepted : 22/09/2015
In Press: 15/10/2015
Published: 16/10/2015
Abstract
Psoriatic arthropathy (PsA) is an inflammatory arthropathy associated with skin or nail psoriasis with heterogeneous clinical manifestations. A pragmatic therapeutic approach to PsA is to stratify the disease manifestations according to their response to synthetic and biological agents. It is now reasonably well established that peripheral arthritis is amenable to treatment with synthetic disease-modifying anti-rheumatic drugs, while psoriatic pelvispondylitis and inflammatory tendon lesions appear to require the use of biological agents. Cyclosporine is a calcineurin inhibitor belonging to the synthetic disease-modifying anti-rheumatic drugs group. It has been shown to be effective in treating both arthritis and psoriasis. In this paper, we will briefly summarise the current knowledge about the efficacy of cyclosporine, both as a monotherapy and as an adjunctive treatment for PsA.
